This study will evaluate the efficacy and safety of SAL0140 in patients with chronic kidney disease (CKD).
Aged ≥18 years , regardless of gender.
Diagnosed with chronic kidney disease (CKD)
Urine albumin-creatinine ratio (UACR) of ≥300 mg/g and ≤5000 mg/g.
Serum potassium≥ lower limit of normal (LLN) and ≤4.8 mmol/L.
Had a documented diagnosis of autosomal dominant polycystic kidney disease or chronic kidney disease associated with infection or malignancy.
Had acute kidney injury or end-stage renal disease, received peritoneal dialysis, hemodialysis or kidney transplantation; or planned to undergo kidney transplantation or chronic renal replacement therapy during the study period.
Mean seated office systolic blood pressure (msSBP) ≥180 mmHg and/or mean seated office diastolic blood pressure (msDBP) ≥110 mmHg. History or diagnosis of malignant hypertension, hypertensive emergency, hypertensive crisis or hypertensive encephalopathy.
History or diagnostic evidence of other secondary hypertension.
Parallel
SAL0140 Tablets
DrugSAL0140 Tablets
SAL0140 Tablets
DrugSAL0140 Tablets
SAL0140 placebo
Drugplacebo
The baseline change of UACR
Change from baseline in UACR compared to placebo at Week 16
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
